CA3175552A1 - Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof - Google Patents

Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Info

Publication number
CA3175552A1
CA3175552A1 CA3175552A CA3175552A CA3175552A1 CA 3175552 A1 CA3175552 A1 CA 3175552A1 CA 3175552 A CA3175552 A CA 3175552A CA 3175552 A CA3175552 A CA 3175552A CA 3175552 A1 CA3175552 A1 CA 3175552A1
Authority
CA
Canada
Prior art keywords
powder
crystalline
pyrrolidin
ylmethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175552A
Other languages
English (en)
French (fr)
Inventor
Axel Becker
Delia-Maria GRUIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3175552A1 publication Critical patent/CA3175552A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3175552A 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof Pending CA3175552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170197 2020-04-17
EP20170197.6 2020-04-17
PCT/EP2021/059604 WO2021209477A1 (en) 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Publications (1)

Publication Number Publication Date
CA3175552A1 true CA3175552A1 (en) 2021-10-21

Family

ID=70333787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175552A Pending CA3175552A1 (en) 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Country Status (8)

Country Link
US (1) US20230295156A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136087A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522023A (cg-RX-API-DMAC7.html)
CN (1) CN115515955A (cg-RX-API-DMAC7.html)
BR (1) BR112022018436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175552A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552366A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209477A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100975895B1 (ko) * 2008-04-29 2010-08-18 강민석 피로나리딘의 제조방법 및 이를 위한 중간체
CN101544638B (zh) * 2009-05-12 2012-05-30 重庆通天药业有限公司 乳酸咯萘啶及其药物组合物
CN103373995B (zh) * 2012-04-28 2016-04-27 上海迪赛诺药业有限公司 一种制备咯萘啶的方法
US9994577B2 (en) * 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
CN105461713A (zh) * 2014-09-25 2016-04-06 刘力 苯并萘啶类的新化合物及其组合物和用途
BR112019006456A2 (pt) * 2016-10-13 2019-06-25 Medicines For Malaria Venture Mmv diespiro 1,2,4-trioxolano, formulação farmacêutica, processo para a preparação de um derivado de diespiro 1,2,4-trioxolano, intermediário, e, método para prevenir e/ou tratar malária e esquistossomose ou um câncer.
MX2020009711A (es) * 2018-04-11 2020-10-07 Merck Patent Gmbh Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.
CN112209926A (zh) * 2019-07-12 2021-01-12 中国中医科学院中药研究所 磷酸咯萘啶的多晶型物及其制备方法、应用
CN116507331A (zh) * 2020-06-15 2023-07-28 默克专利有限公司 Tlr7/8拮抗剂及其用途

Also Published As

Publication number Publication date
CN115515955A (zh) 2022-12-23
BR112022018436A2 (pt) 2022-11-01
WO2021209477A1 (en) 2021-10-21
US20230295156A1 (en) 2023-09-21
EP4136087A1 (en) 2023-02-22
JP2023522023A (ja) 2023-05-26
PH12022552366A1 (en) 2024-03-18

Similar Documents

Publication Publication Date Title
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
US20220119431A1 (en) Salt of egfr inhibitor, crystal form, and preparation method therefor
CN108395443B (zh) 抑制程序性死亡受体配体1的环状化合物及其用途
US11179329B2 (en) Therapeutical use of H3-ligands
EP2314569A1 (en) Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011140858A1 (zh) 枸橼酸爱地那非晶型o及其制备方法和应用
CN118754865B (zh) 黄芩素衍生物及其制备方法和作为胰脂肪酶抑制剂的应用
KR20230104186A (ko) 키나제 억제제의 약제학적 조성물
JP7464613B2 (ja) ジアリールチオヒダントイン化合物結晶
US20230295156A1 (en) Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
KR20240115849A (ko) 라벡시모드 화합물
AU2017340594A1 (en) Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
US10981864B2 (en) Crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
US20240409547A1 (en) Solid Forms of Upadacitinib
CN116120327B (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
CN102040603A (zh) 溴化n-邻甲氧羰基苄基四氢小檗碱及其治疗高血脂症的用途
CN117800938B (zh) 一种羟基取代贝前列素衍生物、合成方法及其应用
JP2009535395A (ja) 9a−置換アザリド
US20190092756A1 (en) Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
CN117751121A (zh) 氨基吡唑并嘧啶化合物的晶体
CN117466898A (zh) 氨基吡唑并嘧啶化合物的晶体
WO2025113494A1 (zh) 多环类化合物及其应用
CN106397410B (zh) 5-羟色胺受体激动剂及其制备方法和用途
TW202539674A (zh) 用作cdk4蛋白激酶抑制劑的化合物及其應用

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250407

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260302

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260320

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260709